The next generation of therapy for multiple myeloma: a review of ongoing clinical trials utilizing ClinicalTrials.gov. (18th July 2018)

• Record Type: Journal Article
• Authors: Barth, Peter; Vale, Colin; Chambers, Alison B; Reagan, John L
• Is Part Of: Future oncology. Volume 14:Number 19(2018)
• Page Start: 1965
• Page End: 1976
• Publication Date: 2018-07-18
• Subjects: biomarkers -- clinical trial design -- clinical trials -- immunotherapy -- minimal residual disease -- multiple myeloma -- quality of life -- targeted therapy; Oncology -- Periodicals; 616.99405
• DOI: 10.2217/fon-2017-0722
• Languages: English
• ISSNs: 1479-6694

Abstract

The therapeutic armamentarium for multiple myeloma has grown significantly over the past decade. We characterized ongoing multiple myeloma clinical trials utilizingClinicalTrials.gov . A search ofClinicalTrials.gov on 21 April 2017 returned 239 therapeutic interventional trials in multiple myeloma. A majority (84.1%) of trials are early-phase (I/II). Immunotherapies are significantly more likely to be studied in Phase I trials than Phase II trials (p = 0.0049). Primary sponsor (academic, cooperative group, industry) is significantly associated with phase of trial (p = 0.0334). Quality of life assessment is included as a secondary objective in only 10.1% of trials. Areas of need are continued advancement of immunotherapies, late-phase studies utilizing a triplet control group, and an objective focus on quality of life.